ASSOCIATION OF THE GENE CYP11B2 WITH THE RISK OF ESSENTIAL HYPERTENSION AND ATHEROTHROMBOTIC COMPLICATIONS
https://doi.org/10.15829/1728-8800-2016-3-63-68
Abstract
Genetics of arterial hypertension is broadly discussed as of one of multifactorial diseases. Invention of an algoritm for risk stratification based upon genetic parameters, gives chance to select groups of higher essential hypertension (EH) risk with the aim of primary prevention. One of such prototypes was assessed, that inculdes 11 genetic markers, in 30 patients with known clinical parameters; 19 of those were with EH and 11 normotonics. Individual impact is assessed of each marker and comparison done for total risk in patients. As a result, there were no differences found in individual risk for patients with and without EH by 11 markers, between subgroups. There was protective effect found for the allele С rs1799998 of gene CYP11B2 (OR 0,247; CI=[0,081-0,754], p=0,01).
About the Authors
E. M. Zelenskaya
Institute of Chemical Biology and Fundamental Medicine of SD RAS, Novosibirsk
Russian Federation
Russian Federation
N. V. Koch
Institute of Chemical Biology and Fundamental Medicine of SD RAS, Novosibirsk;
Novosibirsk State University, Novosibirsk
Russian Federation
Russian Federation
V. V. Kireeva
Irkutsk City Scientific Center of SD RAS, Irkutsk
Russian Federation
Russian Federation
K. A. Apartsin
Irkutsk City Scientific Center of SD RAS, Irkutsk
Russian Federation
Russian Federation
G. I. Lifshitz
Institute of Chemical Biology and Fundamental Medicine of SD RAS, Novosibirsk;
Novosibirsk State University, Novosibirsk
Russian Federation
Russian Federation
References
1. Lifshits GI, Daniel ST, Guskova EV, et al. The association of genes encoding proteins of hemostasis, with the parameters of peripheral hemostasis and susceptibility to atherothrombotic events in patients with cardiovascular diseases. Cardiovascular Therapy and Prevention 2011; 4:90-6. Russian (Лифшиц Г.И., Данилкина С.Т., Гуськова Е.В. и др. Ассоциация генов, кодирующих белки гемостаза, с параметрами периферического гемостаза и предрасположенностью к атеротромбозам у пациентов с сердечно-сосудистыми заболеваниями. Кардиоваскулярная терапия и профилактика 2011; 4: 90-6).
2. Recommendations for the treatment of hypertension. ESH/ESC 2013. Russ J Cardiol 2014; 1 (105): 7-94. Russian (Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013. Российский кардиологический журнал 2014; 1 (105): 7-94).
3. Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens 2010; 23: 1170-8.
4. Nikolaeva AA, Otieva EA, Egorova NA, et al. Cabinet of family counseling in the clinic of the city as a major primary care primary prevention of cardiovascular diseases. Pediatrics. Journal of Speransky G.N. 2001; 80(2): 102-4. Russian (Николаева А.А., Отиева Э.А., Егорова Н.А. и др. Кабинет семейного консультирования в крупной поликлинике города как первичное звено первичной профилактики сердечно-сосудистых заболеваний. Педиатрия. Журнал им. Г.Н. Сперанского 2001; 80(2): 102-4).
5. Kireeva VV, Koh NV, Lifshits GI, et al. Endothelial dysfunction as the cornerstone of cardiovascular events: molecular and pharmacogenetic aspects (review). Russ J Cardiol 2014; 10: 64-8. Russian (Киреева В.В., Кох Н.В., Лифшиц Г.И. и др. Дисфункция эндотелия как краеугольный камень сердечно-сосудистых событий: молекулярнои фармакогенетические аспекты (обзор литературы). Российский кардиологический журнал 2014; 10: 64-8).
6. Nikolaev KY, Kurdoedov AY, Lifshits GI, et al. Option of essential hypertension with severe symptoms of autonomic dysfunction. Hypertension 2000; 6(1):55-7. Russian (Николаев К.Ю., Курдоедов А.Ю., Лифшиц Г.И., и др. Вариант эссенциальной гипертензии с выраженной симптоматикой вегетативных дисфункций. Артериальная гипертензия 2000; 6(1): 55-7).
7. Innocenti F. Pharmacogenomics: Methods and Protocols (Methods in Molecular Biology). Humana Press. 2005: 224.
8. International Consortium for Blood Pressure Genome-Wide Association Studies et al, Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011; 478: 103-9.
9. Koch NV, Lifshits GI. Genetic aspects in the etiology and pharmacotherapy of hypertension. CDL Manual head 2015; 5: 13-21. Russian (Кох Н.В., Лифшиц Г.И. Генетические аспекты в этиологии и фармакотерапии артериальной гипертонии. Справочник заведующего КДЛ 2015; 5: 13-21).
10. Ji L, Cai X, Zhang L, et al. Association between Polymorphisms in the ReninAngiotensin-Aldosterone System Genes and Essential Hypertension in the Han Chinese Population. PLoS ONE 2013; 8(8): e72701.19.
11. Jia M, Zhang H, Song X, et al. Association of CYP11B2 polymorphisms with susceptibility to primary aldosteronism: a meta-analysis. Endocrine J 2013; 60(7): 861-70.
12. Andersen K. Aldosterone synthase inhibition in hypertension. Curr Hypertens Rep 2013; 15(5): 484-8.
13. Ma F, Yang Y, Li X, et al. The Association of Sport Performance with ACE and ACTN3 Genetic Polymorphisms: A Systematic Review and Meta-Analysis. PLoS One 2013; 8(1): e54685.
14. Ned RM, Yesupriya A, Imperatore G, et al. The ACE I/D polymorphism in US adults: limited evidence of association with hypertension-related traits and sex-specific effects by race/ethnicity. Am J Hypertens 2012; 25(2): 209-15.
15. Carstens N, van der Merwe L, Revera M, et al. Genetic variation in angiotensin II type 2 receptor gene influences extent of left ventricular hypertrophy in hypertrophic cardiomyopathy independent of blood pressure. J Renin Angiotensin Aldosterone Syst 2011; 12(3): 274-80.
Review
For citations:
Zelenskaya E.M., Koch N.V., Kireeva V.V., Apartsin K.A., Lifshitz G.I. ASSOCIATION OF THE GENE CYP11B2 WITH THE RISK OF ESSENTIAL HYPERTENSION AND ATHEROTHROMBOTIC COMPLICATIONS. Cardiovascular Therapy and Prevention. 2016;15(3):63-68. (In Russ.) https://doi.org/10.15829/1728-8800-2016-3-63-68
Views:
740
Email this article 
